A new Lancet Psychiatry review examined 54 randomized trials of cannabinoids for mental disorders and substance use disorders, and the evidence was thinner than many public claims suggest. A few outcomes showed signals, especially in cannabis use disorder, sleep-time outcomes in insomnia, tic severity, and autism-related measures, but much of the literature remained low certainty and short-term. This physician-guided review explains what the paper actually found, what it did not test, and how to think about the gap between clinical enthusiasm and evidence quality.
Major Canadian Study Reveals Significant Connection Between Cannabis Use, – Bioengineer.org
WHY IT MATTERS: Patients managing anxiety or depression with cannabis should discuss their specific product, dose, and frequency with a knowledgeable clinician, because the type of cannabis being used matters enormously for mental health outcomes. CLINICAL OVERVIEW: Research continues to build a meaningful association between cannabis use and elevated rates of anxiety and depression, particularly in populations using high-THC products frequently and without medical guidance. The relationship is likely bidirectional, meaning individuals with pre-existing mental health vulnerabilities may be drawn to cannabis for symptom relief while simultaneously facing heightened risk of worsening outcomes depending on how, when, and what they consume.